The Anti-Cancer Effects of Frondoside A
AbstractFrondoside A is a triterpenoid glycoside from the Atlantic Sea Cucumber, Cucumaria frondosa. Frondoside A has a broad spectrum of anti-cancer effects, including induction of cellular apoptosis, inhibition of cancer cell growth, migration, invasion, formation of metastases, and angiogenesis. In cell lines and animal models studied to date, the anti-cancer effects of the compound are seen in all solid cancers, lymphomas, and leukemias studied to date. These effects appear to be due to potent inhibition of p21-activated kinase 1 (PAK1), which is up-regulated in many cancers. In mouse models, frondoside A has synergistic effects with conventional chemotherapeutic agents, such as gemcitabine, paclitaxel, and cisplatin. Frondoside A administration is well-tolerated. No side effects have been reported and the compound has no significant effects on body weight, blood cells, or on hepatic and renal function tests after long-term administration. Frondoside A may be valuable in the treatment of malignancies, either as a single agent or in combination with other therapeutic modalities. View Full-Text
A printed edition of this Special Issue is available here.
Share & Cite This Article
Adrian, T.E.; Collin, P. The Anti-Cancer Effects of Frondoside A. Mar. Drugs 2018, 16, 64.
Adrian TE, Collin P. The Anti-Cancer Effects of Frondoside A. Marine Drugs. 2018; 16(2):64.Chicago/Turabian Style
Adrian, Thomas E.; Collin, Peter. 2018. "The Anti-Cancer Effects of Frondoside A." Mar. Drugs 16, no. 2: 64.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.